AI Analysis | Feedback

Here are 1-3 brief analogies for Revolution Medicines (RVMD):

• Mirati Therapeutics, but focused on the broader RAS(ON) pathway.
• Blueprint Medicines, but for RAS-driven cancers.

AI Analysis | Feedback

• RMC-6236: A potent, first-in-class oral RAS(ON) multi-mutant inhibitor currently in clinical development for various RAS-addicted cancers.
• RMC-9807: An oral RASG12D(ON) selective inhibitor in clinical development, targeting cancers driven by the most prevalent RAS mutation.
• RMC-5147: An oral RASG12C(ON) selective inhibitor in clinical development, designed to specifically target the RAS G12C mutation.
• RMC-8839: An oral RASG12V(ON) selective inhibitor in preclinical development, focused on cancers with the RAS G12V mutation.

AI Analysis | Feedback

Revolution Medicines (symbol: RVMD) is a clinical-stage biotechnology company focused on developing precision oncology therapeutics. As such, the company is primarily engaged in research and development activities and has not yet commercialized any products.

According to its latest SEC filings, Revolution Medicines states: "We have not generated any revenue from product sales." The company's current revenue streams are primarily interest income and, historically, minor collaboration revenue that is not significant to its operations.

Therefore, Revolution Medicines does not currently have "major customers" in the traditional sense, as it does not sell products or services primarily to other companies or to individuals. Its business model at this stage is focused on advancing its pipeline of drug candidates through clinical trials, rather than generating revenue from commercial sales.

AI Analysis | Feedback

null

AI Analysis | Feedback

Mark A. Goldsmith, M.D., Ph.D., Chief Executive Officer, President, and Chairman
Dr. Goldsmith joined Revolution Medicines in November 2014 as Chief Executive Officer and President, and was appointed Chair of the Board in 2020. Prior to his tenure at Revolution Medicines, he held significant leadership roles at other biotechnology companies. He served as President and Chief Executive Officer of Constellation Pharmaceuticals from 2009 to 2012, and later as Chairman from 2012 until its acquisition by MorphoSys AG in July 2021. Dr. Goldsmith also served as the first Chief Executive Officer of both Global Blood Therapeutics (2012-2014) and Nurix, Inc. (2012-2014). He was a Partner with Third Rock Ventures, a life sciences venture capital firm, from 2013 to 2015, and a Venture Partner from 2012 to 2013, indicating a pattern of managing companies with private equity backing.

Jack Anders, Chief Financial Officer
Mr. Anders has served as Chief Financial Officer of Revolution Medicines since September 2022, having previously been Senior Vice President, Finance and Principal Financial and Accounting Officer since joining the company in 2018. Before Revolution Medicines, he spent 12 years at Depomed, Inc., a specialty pharmaceutical company, most recently as Vice President of Finance from 2006 to July 2018. At Depomed, Mr. Anders supported multiple product launches, product acquisitions and divestitures, and capital raises exceeding $1 billion, playing a key role in the company's transformation into a commercial pharmaceutical entity. He began his career at PricewaterhouseCoopers and held various managerial roles in finance and accounting at Elan Pharmaceuticals, Yahoo!, and Novellus Systems.

Margaret A. Horn, J.D., Chief Operating Officer
Ms. Horn has served as Chief Operating Officer of Revolution Medicines since October 2018. She previously held the roles of Executive Vice President and General Counsel at the company from December 2014 to October 2018. With over 30 years of leadership experience in the biotechnology industry, Ms. Horn's prior roles include Chief Operating Officer at ProLynx LLC (2010-2014), Senior Vice President, Legal and Corporate Development at Kosan Biosciences, Inc. (2006-2007), and Senior Vice President, Legal at Genencor International, Inc. (1991-2005). Her expertise encompasses international strategic transactions, global litigation, and numerous public and private financings, including M&A and multiple equity financings.

Daniel Simon, Chief Business Officer
Mr. Simon joined Revolution Medicines as Chief Business Officer in early September 2022. He brings over 15 years of life science industry experience, with expertise spanning business development, strategy, and operations. Prior to joining Revolution Medicines, Mr. Simon was the Senior Vice President, Biopharma Business Development at Guardant Health, where he was responsible for developing and leading a new business unit that supported over 100 biotechnology and pharmaceutical companies and 400 clinical trials.

Jeff Cislini, Senior Vice President, General Counsel and Corporate Secretary
Mr. Cislini was promoted to Senior Vice President, General Counsel and Corporate Secretary in September 2022. He joined Revolution Medicines in 2020 as Deputy General Counsel, serving as the company's senior legal advisor. Before joining Revolution Medicines, Mr. Cislini served as a Vice President at Atara Biotherapeutics. His earlier career included working at the law firms of O'Melveny & Myers and Wilson Sonsini Goodrich & Rosati, where he specialized in general corporate and transactional matters.

AI Analysis | Feedback

The key risks to Revolution Medicines (RVMD) primarily revolve around the inherent challenges of a clinical-stage biotechnology company, operating within a highly competitive market, and managing significant financial outlays for research and development.

1. Clinical Trial and Regulatory Risks: As a clinical-stage oncology company, Revolution Medicines' business is heavily reliant on the successful progression of its product candidates through rigorous clinical trials and ultimately obtaining regulatory approvals. The drug development process is inherently uncertain, and there is no guarantee that the results from previous trials will predict future outcomes. Any delays or failures in these crucial stages or adverse changes in regulatory policies could severely harm the company's ability to bring its therapies to market and generate revenue.
2. Intense Competition in the Oncology Market: Revolution Medicines operates within a highly competitive oncology market, especially in the RAS inhibitor space, which includes numerous established pharmaceutical companies and emerging biotech firms developing similar treatments. Competitors, such as Amgen (with Lumakras) and Mirati Therapeutics (with adagrasib), could introduce effective therapies to the market sooner or demonstrate superior efficacy, thereby potentially limiting Revolution Medicines' market share and revenue potential for its product candidates.
3. Financial Risks (Accumulated Deficit and Cash Burn): Revolution Medicines has a substantial accumulated deficit, reporting nearly $2 billion as of December 31, 2024, and has consistently incurred losses since its inception. The company is not yet profitable, with ongoing negative earnings per share (EPS) forecasts. This high cash burn rate necessitates continuous external funding to support its operations and extensive research and development efforts. Prolonged losses and the need for additional capital could strain the company's resources and potentially lead to dilutive financing rounds, impacting investor confidence and long-term financial stability.

AI Analysis | Feedback

AI Analysis | Feedback

Revolution Medicines (RVMD) is a clinical-stage precision oncology company focused on developing novel targeted therapies for RAS-addicted cancers, with a pipeline of RAS(ON) inhibitors including daraxonrasib (RMC-6236), elironrasib (RMC-6291), and zoldonrasib (RMC-9805).

The addressable market for their main products or services can be summarized as follows:

• The overall RAS pathway inhibitor market is estimated to be a $15–20 billion addressable market by 2030, with a focus on global access.
• For KRAS inhibitors, a significant segment of RAS-addicted cancers, the market across the 7MM (United States, EU4, and Japan) is projected to grow from USD 526 million in 2025 to USD 7.8 billion by 2034. The United States is expected to contribute approximately 70% of this market share.
• Revolution Medicines' lead product, daraxonrasib, a pan-RAS inhibitor, has been projected by analysts to achieve peak sales of more than $7 billion and potentially become an $8 billion drug. This product targets RAS genes, which are implicated in about 22% of all cancers, and has potential applications in pancreatic cancer, colorectal cancer, and lung cancer.

AI Analysis | Feedback

Revolution Medicines (RVMD) is positioned for significant future revenue growth over the next 2-3 years, driven primarily by the advancement and potential commercialization of its innovative RAS(ON) inhibitor pipeline. The key expected drivers include:

1. Commercialization of Daraxonrasib (RMC-6236) in Pancreatic Cancer and Non-Small Cell Lung Cancer (NSCLC): Daraxonrasib, a RAS(ON) multi-selective inhibitor, is Revolution Medicines' lead product candidate. It has received FDA Breakthrough Therapy Designation for previously treated metastatic pancreatic cancer with KRAS G12 mutations and has shown encouraging clinical data in this setting. The company plans to initiate global Phase 3 trials for daraxonrasib in both first-line and second-line metastatic pancreatic ductal adenocarcinoma (PDAC). Additionally, a Phase 3 registrational study for daraxonrasib as monotherapy in previously treated advanced RAS-mutant NSCLC is expected to commence in the first quarter of 2025. These late-stage clinical advancements and regulatory designations signify a strong potential for market entry and revenue generation from this lead asset.

2. Advancement and Potential Approval of Elironrasib (RMC-6291) in NSCLC: Elironrasib, a RAS(ON) G12C-selective inhibitor, has also received FDA Breakthrough Therapy Designation for NSCLC treatment. This designation indicates a potential for accelerated development and regulatory review, paving the way for its introduction into the market and contributing to future revenue growth by addressing a specific RAS mutation in lung cancer.

3. Progression and Future Commercialization of Zoldonrasib (RMC-9805): Zoldonrasib, a RAS(ON) G12D-selective inhibitor, has demonstrated promising preliminary clinical antitumor activity in a Phase 1 monotherapy study, particularly in patients with PDAC, showing a 30% objective response rate and an 80% disease control rate at its candidate recommended Phase 2 dose. As this asset progresses through later-stage clinical trials, it holds significant potential to become a revenue driver by targeting the prevalent KRAS G12D mutation.

4. Expansion of the Broader RAS(ON) Inhibitor Portfolio: Revolution Medicines is developing a comprehensive pipeline of RAS(ON) inhibitors, including preclinical programs such as RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), along with next-generation programs. This broad portfolio aims to target diverse oncogenic RAS variants and develop combination treatment strategies, positioning the company for sustained long-term growth by addressing a wider array of RAS-addicted cancers.

5. Global Market Expansion: The company is actively expanding its global commercialization capabilities. This strategic move indicates plans for international product launches, which will significantly broaden their potential patient base and unlock additional revenue streams beyond the U.S. market.

AI Analysis | Feedback

Share Repurchases

• No information is available regarding share repurchases or authorized future share repurchases by Revolution Medicines over the last 3-5 years. The company has not paid dividends.

Share Issuance

• Revolution Medicines completed its initial public offering (IPO) in February 2020, raising approximately $238 million by issuing about 14 million shares at $17 per share.
• In July 2020, the company conducted a follow-on offering of 5.5 million common shares, generating approximately $159.6 million in net proceeds.
• The number of outstanding shares increased by 15.98% over the last year, as of November 2025.

Inbound Investments

• In June 2025, Revolution Medicines received a $250 million royalty monetization tranche from its partnership with Royalty Pharma.
• An additional $1.75 billion in future committed capital remains under the arrangement with Royalty Pharma.

Outbound Investments

• No significant outbound investments, such as acquisitions of other companies or strategic investments, have been identified from the available information over the last 3-5 years.

Capital Expenditures

• Capital expenditures for Revolution Medicines totaled -$15.29 million over the last 12 months, as of November 2025.
• The primary focus of capital allocation for Revolution Medicines is on its research and development pipeline, specifically the discovery, development, and delivery of innovative, targeted medicines for RAS-addicted cancers.
• Annual cash flow from investing activities, which includes capital expenditures, was -$0.554 billion in 2024, significantly increasing from -$0.343 billion in 2023 and -$0.024 billion in 2022.